Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma

C. R. Divgi, S. Welt, M. Kris, F. X. Real, S. D J Yeh, Richard J. Gralla, B. Merchant, S. Schweighart, M. Unger, S. M. Larson, J. Mendelsohn

Research output: Contribution to journalArticle

260 Citations (Scopus)

Abstract

Murine monoclonal antibody (MAb) 225 (IgG1) against the epidermal growth factor (EGF) receptor competitively blocks EGF binding and inhibits EGF-induced activation of receptor tyrosine kinase and cell proliferation. The effect of MAb 225 was studied in a phase I trial in patients with inoperable squamous cell carcinoma of the lung, which invariably expresses high levels of EGF receptors. Groups of three patients received total doses of MAb 225 ranging from 1 mg to 300 mg. Except at the lowest dose, each infusion included 4 mg of indium 111 (111In)-labeled MAb 225. No toxicity was observed. Tumors were imaged in all patients who received doses of 20 mg or greater. Presumed metastases greater than or equal to 1 cm in diameter were imaged with doses of 40 mg or greater. Single-photon-emission-computed tomography could be carried out at the 120-mg and 300-mg doses and significantly improved tumor visualization. All patients produced anti-murine antibodies. We conclude that treatment with an MAb that inhibits EGF receptor function is safe at the doses and schedule studied. 111In-labeled MAb images squamous cell lung carcinoma; tumor uptake of the labeled MAb is dose dependent. Further studies are warranted to explore the potential therapeutic efficacy of anti-EGF receptor MAbs and other agents that act in a comparable manner.

Original languageEnglish (US)
Pages (from-to)97-104
Number of pages8
JournalJournal of the National Cancer Institute
Volume83
Issue number2
StatePublished - Jan 16 1991
Externally publishedYes

Fingerprint

Indium
Monoclonal antibodies
Monoclonal Antibody
Growth Factors
Lung
Epidermal Growth Factor Receptor
Receptor
Squamous Cell Carcinoma
Dose
Monoclonal Antibodies
Imaging
Imaging techniques
Cell
Tumors
Tumor
Epidermal Growth Factor
Phase I Trial
Single photon emission computed tomography
Neoplasms
Metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Physiology (medical)
  • Radiology Nuclear Medicine and imaging

Cite this

Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. / Divgi, C. R.; Welt, S.; Kris, M.; Real, F. X.; Yeh, S. D J; Gralla, Richard J.; Merchant, B.; Schweighart, S.; Unger, M.; Larson, S. M.; Mendelsohn, J.

In: Journal of the National Cancer Institute, Vol. 83, No. 2, 16.01.1991, p. 97-104.

Research output: Contribution to journalArticle

Divgi, CR, Welt, S, Kris, M, Real, FX, Yeh, SDJ, Gralla, RJ, Merchant, B, Schweighart, S, Unger, M, Larson, SM & Mendelsohn, J 1991, 'Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma', Journal of the National Cancer Institute, vol. 83, no. 2, pp. 97-104.
Divgi, C. R. ; Welt, S. ; Kris, M. ; Real, F. X. ; Yeh, S. D J ; Gralla, Richard J. ; Merchant, B. ; Schweighart, S. ; Unger, M. ; Larson, S. M. ; Mendelsohn, J. / Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. In: Journal of the National Cancer Institute. 1991 ; Vol. 83, No. 2. pp. 97-104.
@article{10fc6452a083420590cab92f2e2af469,
title = "Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma",
abstract = "Murine monoclonal antibody (MAb) 225 (IgG1) against the epidermal growth factor (EGF) receptor competitively blocks EGF binding and inhibits EGF-induced activation of receptor tyrosine kinase and cell proliferation. The effect of MAb 225 was studied in a phase I trial in patients with inoperable squamous cell carcinoma of the lung, which invariably expresses high levels of EGF receptors. Groups of three patients received total doses of MAb 225 ranging from 1 mg to 300 mg. Except at the lowest dose, each infusion included 4 mg of indium 111 (111In)-labeled MAb 225. No toxicity was observed. Tumors were imaged in all patients who received doses of 20 mg or greater. Presumed metastases greater than or equal to 1 cm in diameter were imaged with doses of 40 mg or greater. Single-photon-emission-computed tomography could be carried out at the 120-mg and 300-mg doses and significantly improved tumor visualization. All patients produced anti-murine antibodies. We conclude that treatment with an MAb that inhibits EGF receptor function is safe at the doses and schedule studied. 111In-labeled MAb images squamous cell lung carcinoma; tumor uptake of the labeled MAb is dose dependent. Further studies are warranted to explore the potential therapeutic efficacy of anti-EGF receptor MAbs and other agents that act in a comparable manner.",
author = "Divgi, {C. R.} and S. Welt and M. Kris and Real, {F. X.} and Yeh, {S. D J} and Gralla, {Richard J.} and B. Merchant and S. Schweighart and M. Unger and Larson, {S. M.} and J. Mendelsohn",
year = "1991",
month = "1",
day = "16",
language = "English (US)",
volume = "83",
pages = "97--104",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma

AU - Divgi, C. R.

AU - Welt, S.

AU - Kris, M.

AU - Real, F. X.

AU - Yeh, S. D J

AU - Gralla, Richard J.

AU - Merchant, B.

AU - Schweighart, S.

AU - Unger, M.

AU - Larson, S. M.

AU - Mendelsohn, J.

PY - 1991/1/16

Y1 - 1991/1/16

N2 - Murine monoclonal antibody (MAb) 225 (IgG1) against the epidermal growth factor (EGF) receptor competitively blocks EGF binding and inhibits EGF-induced activation of receptor tyrosine kinase and cell proliferation. The effect of MAb 225 was studied in a phase I trial in patients with inoperable squamous cell carcinoma of the lung, which invariably expresses high levels of EGF receptors. Groups of three patients received total doses of MAb 225 ranging from 1 mg to 300 mg. Except at the lowest dose, each infusion included 4 mg of indium 111 (111In)-labeled MAb 225. No toxicity was observed. Tumors were imaged in all patients who received doses of 20 mg or greater. Presumed metastases greater than or equal to 1 cm in diameter were imaged with doses of 40 mg or greater. Single-photon-emission-computed tomography could be carried out at the 120-mg and 300-mg doses and significantly improved tumor visualization. All patients produced anti-murine antibodies. We conclude that treatment with an MAb that inhibits EGF receptor function is safe at the doses and schedule studied. 111In-labeled MAb images squamous cell lung carcinoma; tumor uptake of the labeled MAb is dose dependent. Further studies are warranted to explore the potential therapeutic efficacy of anti-EGF receptor MAbs and other agents that act in a comparable manner.

AB - Murine monoclonal antibody (MAb) 225 (IgG1) against the epidermal growth factor (EGF) receptor competitively blocks EGF binding and inhibits EGF-induced activation of receptor tyrosine kinase and cell proliferation. The effect of MAb 225 was studied in a phase I trial in patients with inoperable squamous cell carcinoma of the lung, which invariably expresses high levels of EGF receptors. Groups of three patients received total doses of MAb 225 ranging from 1 mg to 300 mg. Except at the lowest dose, each infusion included 4 mg of indium 111 (111In)-labeled MAb 225. No toxicity was observed. Tumors were imaged in all patients who received doses of 20 mg or greater. Presumed metastases greater than or equal to 1 cm in diameter were imaged with doses of 40 mg or greater. Single-photon-emission-computed tomography could be carried out at the 120-mg and 300-mg doses and significantly improved tumor visualization. All patients produced anti-murine antibodies. We conclude that treatment with an MAb that inhibits EGF receptor function is safe at the doses and schedule studied. 111In-labeled MAb images squamous cell lung carcinoma; tumor uptake of the labeled MAb is dose dependent. Further studies are warranted to explore the potential therapeutic efficacy of anti-EGF receptor MAbs and other agents that act in a comparable manner.

UR - http://www.scopus.com/inward/record.url?scp=0026426157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026426157&partnerID=8YFLogxK

M3 - Article

VL - 83

SP - 97

EP - 104

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 2

ER -